Administration

行政

• 批准号: 10158410
• 负责人: Ruth Margrit Ruprecht
• 金额: $ 13.41万
• 依托单位: UNIVERSITY OF LOUISIANA AT LAFAYETTE
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-05-01 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10158410
• 关键词: Achievement; Acquired Immunodeficiency Syndrome; Address; Area; Biomedical Research; Biotechnology; Budgets; Businesses; Cold Chains; Collaborations; Communication; Country; Europe; European; Goals; HIV vaccine; HIV-1; Image; Immunology; Individual; Infectious Agent; Institutes; Institution; Intellectual Property; Lead; Louisiana; Macaca mulatta; Manuscripts; Medicine; Modeling; Monitor; Mucous Membrane; National Institute of Allergy and Infectious Disease; Needles; Oral; Positron-Emission Tomography; Primates; Protocols documentation; Publications; Radionuclide Imaging; Reagent; Reporting; Research; Research Institute; Research Personnel; Resources; Sampling; Science; Scientist; Ships; Site Visit; Solid; Switzerland; Technology; Texas; Time; Training; Travel; United States National Institutes of Health; Universities; Vaccines; Viral Pathogenesis; Virginia; Virosomes; Visit; Washington; base; capsule; data dissemination; design; dosage; experimental study; ileum; immunogenicity; innovation; manufacturing process; material transfer agreement; meetings; nonhuman primate; novel vaccines; payment; prevent; programs; simian human immunodeficiency virus; skills; vaccine delivery; vaccine development; whole body imaging

The overall objective of administrative Core A is to provide this multi-PI, multi-institutional U19 IPCAVD Project the opportunity to interact synergistically by facilitating the communication among the Project Leaders and all participating scientists. Core A will also serve as liaison between Research Administration at the contact institution, the Texas Biomedical Research Institute (TxBiomed), all the affiliated institutions both in the US and in Europe, and NIAD representatives. The network of partnering scientists includes researchers in Texas, Louisiana, Georgia and several countries in Europe; the major partner is Mymetics in Switzerland. The innovative biotech company has developed gp41-based virosomes into to a novel vaccine platform that is cold-chain independent and can be administered mucosally without needles. The Specific Aims of Core A are to: 1. Provide administrative support and facilitate the collaboration among Projects 1 and 2 and the various subcontract/subaward leaders and partners. This will include the exchange of information, reagents, and material transfer agreements. 2. Set priorities, monitor progress and jointly make go/no-go decisions. This will be achieved with input from the External Scientific Advisory Board (ESAB) and the NIAID IPCAVD Program Officer. 3. Assist in the design of experiments in rhesus macaques (RMs), protocol design and submission, and exchange of samples between the New Iberia Research Center (NIRC), where the primate studies will be conducted, and TxBiomed. 4. Provide statistical support for all IPCAVD scientists through the participation of Dr. Sarah Ratcliffe through a subaward with the University of Virginia (UVA). 5. Provide financial oversight and assure prompt payment of bills as well as the timely achievement of the experimental goals within budget limits. 6. Organize the yearly NIH Site Visit and the External Scientific Advisory Board (ESAB) meeting in the Washington, D.C. area, as well as individual visits between Drs. Ruprecht, Villinger, Santangelo and Fleury. 7. Address intellectual property (IP) issues fairly, timely, and equitably. 8. Facilitate the submission of reports, dissemination of data at meetings, and publication of manuscripts. To meet the goals of this translational, highly interactive U19 Research Program, the Core A Leader/Contact PI depends on the trained professionals with excellent organization skills as well as basic understanding of science and medicine to make this U19 network of scientists successful.

管理核心A的总体目标是提供这个多PI、多机构U19 IPCAVD项目 通过促进项目负责人和所有人之间的沟通， 参与的科学家核心A还将作为研究管理部门与联络人之间的联络人， 德克萨斯生物医学研究所（TxBiomed），美国所有的附属机构， 在欧洲，和NIAD代表。合作科学家网络包括德克萨斯州的研究人员， 路易斯安那州、格鲁吉亚和欧洲几个国家;主要合作伙伴是瑞士的Mymetics。创新 一家生物技术公司已经将基于gp 41的病毒体开发成一种新型疫苗平台， 其是独立的，并且可以在没有针头的情况下通过粘膜施用。 核心A的具体目标是： 1.提供行政支助，促进项目1和项目2之间的合作， 合同/子合同负责人和合作伙伴。这将包括交换信息、试剂， 材料转让协议。 2.确定优先事项，监控进度，共同做出行动/不行动的决定。这将通过投入来实现 外部科学咨询委员会（ESAB）和NIAID IPCAVD项目官员。 3.协助恒河猴（RM）实验设计，方案设计和提交，以及 新伊比利亚研究中心（NIRC）之间交换样本，灵长类动物研究将 和TxBiomed。 4.通过Sarah Ratcliffe博士的参与为所有IPCAVD科学家提供统计支持 通过弗吉尼亚大学（UVA）的子奖项。 5.提供财务监督，确保及时支付账单，并及时实现 在预算范围内进行实验。 6.组织每年一次的NIH现场访问和外部科学咨询委员会（ESAB）会议， 华盛顿，华盛顿特区地区，以及鲁普雷希特博士、维林格博士、桑坦杰洛博士和 弗勒里 7.公平、及时、公正地解决知识产权问题。 8.为提交报告、在会议上传播数据和出版手稿提供便利。 为了实现这个翻译，高度互动的U19研究计划的目标，核心A领导者/联系PI 这取决于训练有素的专业人员，他们具有出色的组织能力和对科学的基本理解 和医学来使这个U19科学家网络取得成功。